PeptiDream inks research deal with BIND Therapeutics

Japan’s PeptiDream (TYO: 4587) has entered into a research collaboration with USA-based BIND Therapeutics (Nasdaq: BIND).

PeptiDream intends to use its Peptide Discovery Platform System (PDPS) technology to identify macrocyclic peptides that can be utilized as biologically active targeting ligands with BIND’s proprietary Accurin nanoparticles (ACCURINS). BIND has selected targeting ligands of interest to accelerate the company’s innovative medicines strategy focused on products that elicit tumor cell death and modulate the tumor microenvironment to maximize clinical benefit for patients

The company believes combining these Accurin attributes provides a high value platform for innovative medicine discovery. PeptiDream and BIND’s collaboration is designed to investigate the use of PeptiDream’s macrocyclic peptides as the targeting ligand component for ACCURINSaimed at modulating anti-tumor immunity.